NCT04310072

Brief Summary

The investigators evaluated the effects of neuromuscular electrical stimulation (NMES) therapy on functional capacity and oxidative stress in patients hospitalized for an episode of acute heart failure (AHF). The NMES therapy was used on top of the conventional rehabilitation program. After randomization the investigators followed the patients by measuring the evolution of functional capacity, oxidative stress and adverse events.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
30

participants targeted

Target at P25-P50 for not_applicable heart-failure

Timeline
Completed

Started Sep 2019

Shorter than P25 for not_applicable heart-failure

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

September 10, 2019

Completed
2 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

November 20, 2019

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

November 20, 2019

Completed
4 months until next milestone

First Submitted

Initial submission to the registry

March 9, 2020

Completed
8 days until next milestone

First Posted

Study publicly available on registry

March 17, 2020

Completed
Last Updated

March 18, 2020

Status Verified

March 1, 2020

Enrollment Period

2 months

First QC Date

March 9, 2020

Last Update Submit

March 16, 2020

Conditions

Keywords

Cardiac rehabilitationNouromuscular electrical stimulation

Outcome Measures

Primary Outcomes (2)

  • evaluate the impact of NMES therapy applied during hospitalization on the functional capacity

    The investigators will measure 6 minute walk test at the inclusion in the trial ans at the time of discharge

    up to one month (30 days)

  • evaluate the impact of NMES therapy on oxidative stress

    The investigator will measure oxidized LDL plasmatic levels at the inclusion in the trial ans at the time of discharge

    up to one month (30 days)

Study Arms (2)

neuromuscular electrical stimulation group

EXPERIMENTAL

For patients who underwent NMES therapy, four electrodes (two 50/100 mm and two 50/50 mm, Compex Performance) were placed on the skin above the quadriceps muscle approximately 5 cm below the inguinal fold and 3 cm above the upper patella border. The electrical stimulation protocol consisted of electrical current at frequency of 10 Hz, 20 seconds stimulation time (time on) and 20 seconds resting time (time off) with variable intensity (until visible muscular contraction) for one hour per day until discharge (Compex).The NMES therapy was on top of conventional rehabilitation described below.

Device: Neuromuscular electrical stimulation

Control group

NO INTERVENTION

The control group consisted of patients who performed daily active upper and lower limbs exercise in bed and in a stand position (3x10 repetitions, "somewhat hard" on the Borg scale).

Interventions

NMES therapy induces visible rhythmic and repeated muscle contractions without volitional effort from the patient by applying electrodes to the thigh and/or calf muscles.

neuromuscular electrical stimulation group

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • patients with acute heart failure and a LVEF below 50% (echocardiography), admitted consecutively to the cardiology clinic of "Sfantul Pantelimon" Hospital, Bucharest

You may not qualify if:

  • age under 18 years,
  • acute coronary syndrome in the last month,
  • recent myocardial revascularization (in the last 6 weeks),
  • severe ischemic lesions at the level of the lower limbs,
  • life-threatening arrhythmias,
  • uncontrolled blood pressure,
  • high-grade atrioventricular block,
  • acute myocarditis,
  • acute pericarditis,
  • obstructive hypertrophic cardiomyopathy,
  • acute systemic disease,
  • deep vein thrombosis,
  • severe uncorrected primary valvular disease,
  • psychiatric disorders or marked cognitive impairment,
  • active neoplastic disorders except basal or squamous cell carcinoma,
  • +2 more criteria

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Spitalul Sfantul Pantelimon

Bucharest, București, 021660, Romania

Location

Related Publications (1)

  • Ploesteanu RL, Nechita AC, Turcu D, Manolescu BN, Stamate SC, Berteanu M. Effects of neuromuscular electrical stimulation in patients with heart failure - review. J Med Life. 2018 Apr-Jun;11(2):107-118.

MeSH Terms

Conditions

Heart Failure

Condition Hierarchy (Ancestors)

Heart DiseasesCardiovascular Diseases

Study Officials

  • Mihai Berteanu

    Elias Emergency Hospital

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
SINGLE
Who Masked
OUTCOMES ASSESSOR
Masking Details
After the patients were evaluated for inclusion in the study and after signing the informed consent form, they were randomized using the website www.randomization.com (1 complete randomized block). Considering our intervention protocol, it was not possible to blind the patients and/or the investigator who performed the electrostimulation. However, the other investigators who conducted the 6MWT and performed the randomization were blinded.
Purpose
SUPPORTIVE CARE
Intervention Model
PARALLEL
Model Details: The study team conducted a prospective randomized study to investigate the effects of NMES versus standard therapy on a hospitalized population with AHF. After the patients with AHF were stabilized they were included in the trial and were randomized by a blinded investigator to control group or NMES therapy. At the time of enrollment, patients were clinically evaluated and their associated comorbidities and drug therapy were noted. ECG, echocardiography, 6-minute walk test (6MWT) were performed and laboratory samples were collected including oxidized LDL, NT- proBNP, CK, uric acid, lipid profile and PCR. At the time of discharge, all patients underwent a 6MWT and laboratory samples such as oxidized LDL and NT-proBNP were collected again. During the hospitalization period we monitored any adverse events and tolerance to NMES therapy. At the time of inclusion in the study, patients signed an informed consent form in two copies, one remaining with the patient.
Sponsor Type
OTHER
Responsible Party
SPONSOR INVESTIGATOR
PI Title
principal investigator

Study Record Dates

First Submitted

March 9, 2020

First Posted

March 17, 2020

Study Start

September 10, 2019

Primary Completion

November 20, 2019

Study Completion

November 20, 2019

Last Updated

March 18, 2020

Record last verified: 2020-03

Data Sharing

IPD Sharing
Will share

All the individual participant data can be available by email on request. This study is a part of a PhD thesis and a publication of the results will follow

Shared Documents
STUDY PROTOCOL, SAP, ICF, CSR, ANALYTIC CODE
Time Frame
The data is available from the present and 15 years from now
Access Criteria
all the data can be accessed by request on email

Locations